OncRef

Clinical Trial: NCT04569032

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Seagen, a wholly owned subsidiary of Pfizer
Information Provided By:Seagen Inc.
Last Update Posted:2026-08-13

Study Overview

Brief Summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

Official Title

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

Conditions

Peripheral T-cell Lymphoma

Intervention / Treatment

  • Drug: brentuximab vedotin
  • Drug: cyclophosphamide
  • Drug: doxorubicin
  • Drug: prednisone

Other Study ID Numbers

  • SGN35-032

Start Date (Actual)

2020-11-12

Primary Completion Date (Actual)

2024-05-09

Study Completion Date (Actual)

2026-01-12

Enrollment (Actual)

82

Study Type

Interventional

Phase

Phase 2